Skip to main content

Table 4 Subgroup analysis for the effect of statin therapy on myocardial infarction

From: Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials

Subgroup Value Reference Statin Control Relative risk (95% CI) p value Heterogeneity p value for heterogeneity
    Event/total Event/total     
Mean Age > = 65 29,32-34 92/2913 145/2948 0.66 [0.51, 0.85] 0.001 0% 0.44
  <65 24,25 10/480 16/477 0.63 [0.27, 1.47] 0.283 3% 0.31
Cardiovascular History Yes 29,34 82/1130 119/1160 0.67 [0.14, 3.22] 0.012 0% 0.53
  No 25,32 4/192 7/205 0.71 [0.54, 0.93] 0.613 25.1% 0.25
Baseline Creatinine > = 1.5 25,29 19/333 30/339 0.64 [0.37, 1.12] 0.120 0% 0.34
  <1.5 24,32,34 75/1422 111/1457 0.70 [0.53, 0.93] 0.013 0% 0.55
Baseline LDL Cholesterol > = 3.0 24,25, 29,32,34 94/1755 141/1796 0.69 [0.53, 0.88] 0.003 0% 0.704
  <3.0 33 8/1638 20/1629 0.40 [0.18, 0.90] 0.027 - -
LDL Cholesterol Lowering > = 30% 29,33 25/1924 49/1922 0.52 [0.33, 0.84] 0.007 0% 0.418
  <30% 24,25,32 12/625 22/636 0.55 [0.27, 1.13] 0.104 0% 0.505
Follow-up time > = 3 24,29,32, 34 92/1708 140/1750 0.68 [0.53, 0.87] 0.003 0% 0.70
  <3 25,33 10/1685 21/1675 0.59 [0.15, 2.27] 0.443 36% 0.21
  1. Abbreviations: CI confidential interval, LDL low density lipoprotein.